Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective Treatment-resistant depression has recently emerged as a marker of increased risk for morbidity and mortality in patients with coronary heart disease (CHD). Studies in depressed patients without CHD suggest that elevated markers of inflammation predict poor response to treatment. This may help to explain the increased risk of cardiac events associated with depression. We therefore studied the relationship between pre-treatment markers of inflammation and treatment response in patients with CHD and major depression. Methods This was a planned, secondary analysis of a clinical trial in which 122 patients with CHD and comorbid major depression were randomly assigned to 50mg of sertraline plus 2g/day omega-3 fatty acids or to 50mg of sertraline plus 2g/day corn oil placebo capsules for ten weeks. Depressive symptoms were assessed with the Beck Depression Inventory-II (BDI-II). Blood samples were collected at baseline to determine levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). The primary outcome was the post-treatment BDI-II depression score. Results Baseline levels of hs-CRP, IL-6, and TNF-α were not associated with the 10-week post-treatment depression score (p=0.89, p=0.88, and p=0.31, respectively). Treatment responders (>50% reduction from baseline BDI-II score) did not differ from non-responders in either baseline hs-CRP, IL-6, or TNF-α (p=0.83, p=0.93, and p=0.24, respectively). Similarly, depression remitters (BDI-II ≤8 at post-treatment) did not differ from non-remitters on the three baseline inflammation markers. Conclusion These findings do not support the hypothesis that elevated baseline inflammatory markers predict poor response to sertraline in patients with CHD and major depression. The explanation for the increased risk of cardiac events associated with poor response to depression treatment remains unclear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525 · cited 1×
“However, although there is some evidence that omega-3 fatty acids have anti-inflammatory properties [21], we did not observe any significant interactions between allocation to omega-3 fatty acids or placebo and inflammation in relation to depression outcomes.”
BackgroundClinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513 · cited 1×
“Furthermore, systemic inflammatory markers can be affected by fever, injuries, acute infections [24].”
BackgroundDepression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis
Barth, J., Schumacher, M., & Herrmann-Lingen, C. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000146332.53619.b2 · Cited by 1,358 · cited 2×
“Depression is related to increased cardiac morbidity and mortality in patients with CHD [1,2].”
Backgroundvan Melle, J. P., de Jonge, P., Spijkerman, T. A., Tijssen, J. G. P., Ormel, J., van Veldhuisen, D. J., van den Brink, R. H. S., & van den Berg, M. P. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000146294.82810.9c · Cited by 1,034
Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study
Cesari, M., Penninx, B. W. J. H., Newman, A. B., Kritchevsky, S. B., Nicklas, B. J., Sutton-Tyrrell, K., Rubin, S. M., Ding, J., Simonsick, E. M., Harris, T. B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000097109.90783.fc · Cited by 978
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · cited 4×
“observed significantly higher baseline release of IL-6 from peripheral mononuclear cells in nonresponders compared to responders in a sample of depressed patients without heart disease [9].”
BackgroundInfluentialPro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder
Eller, T., Vasar, V., Shlik, J., & Maron, E. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.015 · Cited by 290 · cited 2×
“found that higher levels of TNF-α were related to non-response to escitalopram [10].”
A psychoneuroimmunological review on cytokines involved in antidepressant treatment response
Janssen, D. G. A., Caniato, R. N., Verster, J. C., & Baune, B. T. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1103 · Cited by 240 · cited 1×
“A recent systematic review of the literature noted that antidepressant medications affect cytokine levels, and that this mechanism appears to influence treatment outcome in depression [16].”
BackgroundTreatment-Resistant Depression and Mortality After Acute Coronary Syndrome
Carney, R. M., & Freedland, K. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081239 · Cited by 163 · cited 2×
“Patients with treatment-resistant depression may be at especially high risk of adverse cardiovascular outcomes, and it has been suggested that inflammation may help explain poor responsiveness to depression treatment [5].”
BackgroundSelf-citation
Cited by
Uher, R., Tansey, K. E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010094 · Cited by 418
Lopresti, A. L., Maker, G. L., Hood, S. D., & Drummond, P. D. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.017 · Cited by 371
Omega-3 fatty acids for depression in adults
Appleton, K. M., Sallis, H. M., Perry, R., Ness, A. R., & Churchill, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub4 · Cited by 180
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936486 · Cited by 128
“However, other publications have reported no correlations between inflammation and remission (Bot et al., 2011; Liu et al., 2019).”
BackgroundOmega-3 fatty acids for depression in adults
Appleton, K. M., Voyias, P. D., Sallis, H. M., Dawson, S., Ness, A. R., Churchill, R., & Perry, R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub5 · Cited by 84
Metadata
- Authors
- Bot, M., Carney, R. M., Freedland, K. E., Rubin, E. H., Rich, M. W., Steinmeyer, B. C., & Mann, D. L.
- Venue
- Journal of Psychosomatic Research
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 71
- Issue
- 1
- Pages
- 13-17
- ISSN
- 0022-3999 (ISSN-L)
- OpenAlex
- W2063392547
- Cited by
- 41
- References
- 9
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. https://app.cochat.ai/papers/10.1016/j.jpsychores.2010.11.006
- The paper
- Bot, M., Carney, R. M., Freedland, K. E., Rubin, E. H., Rich, M. W., Steinmeyer, B. C., & Mann, D. L. (2011). Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research. https://doi.org/10.1016/j.jpsychores.2010.11.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.